Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018)

Objective To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL. Methods Twenty-two patients (median age: 65 years) with aggressi...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2019/08/01, Vol.58(15), pp.2159-2166
Main Authors: Kawano, Noriaki, Yoshida, Noriaki, Kawano, Sayaka, Arakawa, Fumiko, Miyoshi, Hiroaki, Yamada, Kyohei, Nakashima, Kazutaka, Yoshida, Shuro, Kuriyama, Takuro, Tochigi, Taro, Nakaike, Takashi, Shimokawa, Tomonori, Yamashita, Kiyoshi, Marutsuka, Kousuke, Mashiba, Koichi, Kikuchi, Ikuo, Ohshima, Koichi
Format: Article
Language:English
Subjects:
ATL
Clinical outcomes
Genetic analysis
Immunology
Internal medicine
Leukemia
Lymphocytes T
Lymphoma
mogamulizumab
Mutation
NS mutation and FS mutation
Original
overall response rate
overall survival
Patients
somatic CCR4 mutation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To elucidate the clinical impact of humanized CCR4 antibody (mogamulizumab) on adult T-cell leukemia-lymphoma (ATL), we retrospectively analyzed the clinical and pathological features and treatment outcomes of aggressive ATL. Methods Twenty-two patients (median age: 65 years) with aggressive ATL [acute- (n=16) or lymphoma-type (n=6)] had their characteristics analyzed. All cases were treated with mogamulizumab at our institution from 2012 to 2018. In addition, we subjected 14 specimens of ATL to histological, immunological, and genetic analyses. Results Regarding the patient outcomes, the overall response rates were 68.1% and 31.8% after 4 and 8 courses (or after the final courses), respectively. The median overall survival (OS) was 95.5 days, while the OS rates at 6 and 12 months were 31.5% and 21.1%, respectively. Concerning patient pathological characteristics, 6 of the 14 patients examined (42.9%) had CCR4 mutations. Regarding the clinicopathological findings related to the mogamulizumab response, notably, the cases with somatic CCR4 mutation tended to have a poorer response (16.7%) than those with wild-type CCR4 (62.5%) after 4 cycles of mogamulizumab. Furthermore, the CCR4 global score tended to be higher in the responder cases than in the non-responder cases. Conclusion The present findings suggest that the CCR4 expression may be related to the mogamulizumab response, although no other significant predictive markers were identified in this study. Further studies will be needed in order to identify more markers related to the mogamulizumab response.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.2513-18